Sun Pharma Distributors Ltd. has issued a precautionary recall for 10 of its eye drop brands, citing concerns over possible contamination. The company communicated this decision in a confidential letter dated July 17, with the news becoming public on August 2, 2026.
Distributors have been instructed to immediately cease billing and selling the affected products and to return all available stock to the company. This measure is described as a "precautionary step" to ensure patient safety.
Affected Products Listed
The recall impacts a range of eye care products. According to the company's letter, the affected items include:
- Depopred2ML
- Brinolar (BKC FREE)
- Brinzotim Eye Drops 5ML BKC FREE
- Lotepred-5ML
- Lotepred 1% Eye Drops SML
- Lotepred LS 0.2% E/D 5ML
- Lotepred T
- Nepalact OD Eye Drops 3ML
- Nepalact-Z
- Toba-F
- Nepalact E/D 5ML
A spokesperson for Sun Pharma affirmed the company's commitment to patient safety, stating, "Patient safety remains our highest priority. We have taken all necessary steps in the best interest of patients and in accordance with applicable regulatory requirements. Our teams are working diligently to restore the availability of these products so that patients continue to have access to these treatment options."
Expert Advice for Patients
An eye care expert highlighted the critical nature of these products, noting that many are prescribed for patients recovering from eye surgery or managing chronic conditions such as glaucoma, eye infections, allergies, and ocular inflammation. "Interruption of treatment can have significant consequences," the expert warned.
The expert also emphasized the non-negotiable importance of maintaining sterility in pharmaceutical manufacturing, especially in a country like India where millions rely on eye drops daily. "Even suspected contamination at a manufacturing facility can pose a serious risk to patient safety, making immediate product recalls essential," they added.
Patients currently using any of the recalled eye drops are advised not to discontinue treatment independently. Instead, they should promptly contact their ophthalmologist to arrange for an appropriate alternative prescription, ensuring continuity of care and safeguarding their vision.